Rationale for Bispecific-Based Combinations in MM

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Related Videos
Experts on RCC
Experts on RCC
Experts on multiple myeloma
Experts on multiple myeloma
Experts on RCC
Experts on RCC
Related Content